Denmark, Norway, Iceland Temporarily Suspend Use Of AstraZeneca’s COVID-19 Vaccine Over Blood Clot Concerns AstraZeneca 

Denmark, Norway and Iceland have temporarily suspended the use of AstraZeneca's COVID-19 vaccine over the concerns that the patients were developing blood clots after receiving the doses, reports Economic Times.

First to announce the temporary suspension, Denmark has however stressed that its a precautionary move and that it has not been determined, at the time being, that there is a link between the vaccine and the blood clots.

It should be noted that the European Medicines Agency (EMA) and also the pharmaceutical giant which has developed the vaccine have insisted that the vaccine is safe to use. EMA has said that as of 9 March, 22 cases of blood clots had been reported among more than three million people vaccinated in the European Economic Area.

Austria had meanwhile on Monday (8 March) suspended the use of a particular batch of AstraZeneca's vaccines after the death of a 49-years-old nurse due to "severe blood coagulation problems" which had come up after she had received her vaccine shot.

Following this, Estonia, Latvia, Lithuania and Luxemburg have also suspended the use of doses received under the batch which was distributed among 17 European nations and comprised of one million doses.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Advertisement